XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Part of paid clinical trials in Anchorage, Alaska.

Sponsor
Xencor, Inc.
Study ID
NCT05005728
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • vudalimab + carboplatin + cabazitaxel — COMBINATION_PRODUCT
    Vudalimab IV, carboplatin IV, cabazitaxel IV
  • vudalimab + olaparib — COMBINATION_PRODUCT
    Vudalimab IV, olaparib oral
  • vudalimab monotherapy — BIOLOGICAL
    Vudalimab IV
  • vudalimab + docetaxel — COMBINATION_PRODUCT
    Vudalimab IV, docetaxel IV
  • vudalimab + cabazitaxel or docetaxel — COMBINATION_PRODUCT
    Vudalimab IV, cabazitaxel or docetaxel IV

Study Details

This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.

Key Dates

Start date
Oct 22, 2021
Status verified
May 2026
Primary completion
Jun 10, 2025
Completion
Jun 10, 2025

Study Design

Enrollment
72 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Cohort A - AVPCa
  • Experimental: Cohort B - HRD/CDK12 PARP - Progressors
  • Experimental: Cohort C - HRD/CDK12 PARP Naïve
  • Experimental: Cohort D - MSI-H, MMRD or TMB-H
  • Experimental: Cohort E - No Targetable Mutations

Primary Outcome Measure

Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab) [ Time Frame: 8 weeks ]

Locations (26)

FacilityCityStateZIPSite coordinators
Alaska Oncology and HematologyAnchorageAlaska99508-
Palo Verde Hematology OncologyGlendaleArizona85304-
Mayo Clinic HospitalPhoenixArizona85054-
City of HopeDuarteCalifornia91010-
VA Greater Los AngelesLos AngelesCalifornia90064-
University of California, San DiegoSan DiegoCalifornia92093-
Rocky Mountain Cancer CentersLone TreeColorado80124-
Mayo ClinicJacksonvilleFlorida32224-
The University of Chicago Medical CenterChicagoIllinois60637-
University of Iowa Hospitals & ClinicsIowa CityIowa52242-
University of Kansas Clinical Research CenterFairwayKansas66205-
Mayo ClinicRochesterMinnesota55905-
GU Research Network/Urology Cancer CenterOmahaNebraska68130-
Comprehensive Cancer Centers of NevadaLas VegasNevada89148-
XCancer New Mexico Oncology Hematology Consultants, Ltd.AlbuquerqueNew Mexico87109-
Columbia UniversityNew YorkNew York10032-
Montefiore Medical CenterThe BronxNew York10461-
Northwest Cancer SpecialistsTigardOregon97223-
University of PennsylvaniaPhiladelphiaPennsylvania19104-
UPMC Hillman Cancer CenterPittsburghPennsylvania15232-
Carolina Urologic Research CenterMyrtle BeachSouth Carolina29572-
SCRI Oncology PartnersNashvilleTennessee37203-
Texas Oncology-Central SouthWeslacoTexas78596-
Virginia Cancer SpecialistsFairfaxVirginia22031-
Virginia Oncology AssociatesNorfolkVirginia23502-
University of Washington/Seattle Cancer Care/AllianceSeattleWashington98109-

Find similar trials in Anchorage, AK

By condition
Prostate cancer
By specialty
OncologyProstate oncologyMen's healthUrology
By research site
Alaska Oncology and Hematology· Anchorage, AKPalo Verde Hematology Oncology· Glendale, AZMayo Clinic Hospital· Phoenix, AZCity of Hope· Duarte, CAVA Greater Los Angeles· Los Angeles, CAUniversity of California, San Diego· San Diego, CA

Related Studies